Sign In
Buy ACET
$7.83
-0.280 (-3.45%)
At Close: Jun 03, 2026
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
02:23pm, Friday, 28'th Nov 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $7.33
01:04am, Tuesday, 25'th Nov 2025
Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. One inve
Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
04:01pm, Wednesday, 05'th Nov 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:59pm, Friday, 31'st Oct 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference
07:00am, Tuesday, 28'th Oct 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA)
07:00am, Thursday, 16'th Oct 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio, Inc. - Special Call
12:35pm, Tuesday, 07'th Oct 2025
Adicet Bio, Inc. - Special Call Company Participants Chen Schor - CEO, President & Director Julie Maltzman - Chief Medical Officer Blake Aftab - Senior VP & Chief Scientific Officer Conference Call Pa
Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2
11:05am, Tuesday, 07'th Oct 2025
Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in aut
Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
07:01am, Tuesday, 07'th Oct 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapie
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
04:27pm, Tuesday, 30'th Sep 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know
01:01pm, Tuesday, 30'th Sep 2025
Adicet Bio (ACET) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:00am, Tuesday, 02'nd Sep 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:48pm, Friday, 29'th Aug 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio (ACET) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 12'th Aug 2025
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
